Pneumonia in patients with chronic kidney disease V D stage: pathogenetic aspects of complex therapy and outcomes
Open Access
- 15 February 2019
- journal article
- Published by Institute of Nephrology of the National Academy of Medical Sciences in Ukrainian Journal of Nephrology and Dialysis
- No. 1(61),p. 20-28
- https://doi.org/10.31450/ukrjnd.1(61).2019.03
Abstract
The aim of our study was to increase the effectiveness of treatment of comorbid pneumonia in patients with CKD VD stage. Materials and Methods. 73 patients with CKD VD st. (59 on HD and 14 on PD) with mild to moderate comorbid pneumonia who received renal replacement therapy (RRT) during 2013-2016 were included in the observational prospective open-label randomized trial. Patients were randomized into two groups: group 1 (n = 42) included patients who in addition to the conventional therapy of pneumonia received medication «Lipin» as a complex therapy; group 2 included patients (n = 31) who received only basic (traditional) therapy. The groups were representative by the main demographic, social and clinical-laboratory findings, severity of pneumonia, duration and modality of RRT. The primary endpoints were death from any cause and episodes of rehospitalization. The overall assessment of the clinical efficacy of the therapy was based on a comparison of the duration of hospitalization, antibiotic therapy, intoxication syndrome, and regression of X-ray changes. Survival in observation groups was determined by the Kaplan-Meier method. Analyzed cases were included to October 31, 2018. The markers of oxidative stress (OS) were determined in 29 patients of group 1 and 14 patients of group 2 before treatment and after 14 days while treatment of pneumonia was started. Results. The analysis demonstrated that during a 1-year period a 17 (25,76%) episodes of rehospitalization were recorded: 11 causes (35.5%) in group 1 and 6 (14.3%) in group 2 (χ² = 4.486, p = 0.035). In total, 29 deaths were recorded during the study period: 10 (23.8%) cases in group 1, and 19 (61.3%) - in group 2 (χ² = 8.957, p = 0.003, RR - 2.574, 95% CI: 1.400-4.733). The three- and five-year cumulative survival rates were 83% vs. 21% and 59% vs. 21%, in the group 1 and group 2, respectively (p = 0.00003). It was stated that the duration of hospitalization, antibiotic therapy, intoxication syndrome and X-ray regression were significantly lower in group 1 compared with group 2 (pKeywords
This publication has 13 references indexed in Scilit:
- US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United StatesAmerican Journal of Kidney Diseases, 2018
- CARRIAGE OF OPPORTUNISTIC MICROORGANISMS AND SURVIVAL OF PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 DUkrainian Journal of Nephrology and Dialysis, 2017
- The clinical and economic burden of pneumonia in patients enrolled in Medicare receiving dialysis: a retrospective, observational cohort studyBMC Nephrology, 2016
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClinical Infectious Diseases, 2016
- HOSPITAL MORBIDITYINPATIENTS WITH CHRONICKIDNEYDISEASE STAGE UDUkrainian Journal of Nephrology and Dialysis, 2014
- Oxidative stress in immunocompetent patients with severe community-acquired pneumonia. A pilot studyMedicina Intensiva (English Edition), 2014
- Relationship between severity of adult community-acquired pneumonia and impairment of the antioxidant defense systemBiological Research, 2013
- The influence of comorbidity on the risk of access-related bacteremia in chronic hemodialysis patientsHemodialysis International, 2009
- Pneumonia in incident dialysis patients--the United States Renal Data SystemNephrology Dialysis Transplantation, 2007
- Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 studyKidney International, 2006